Markets:

Overview

News

Currencies

International

Treasuries

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

0.4566 -0.0222 (-4.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗

June 01, 2023

Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.

Via Talk Markets

Incannex welcomes world-leading psychedelics experts to advisory board

June 01, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group...

Via TheNewswire.com

Incannex welcomes world-leading psychedelics experts to advisory board

June 01, 2023

Incannex welcomes world-leading psychedelics experts to advisory board

Via News Direct

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗

May 23, 2023

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...

Via Benzinga

Why Incannex Healthcare Shares Are Gaining Today ↗

March 15, 2023

Via Benzinga

Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products ↗

March 14, 2023

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

Via Talk Markets

Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary ↗

May 16, 2023

Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.

Via Benzinga

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic ↗

May 05, 2023

Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne.

Via Benzinga

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

May 03, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics...

Via TheNewswire.com

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

May 03, 2023

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

Via News Direct

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗

May 01, 2023

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Via Benzinga

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗

April 25, 2023

Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual...

Via Benzinga

Largest Psychedelic Stocks -3.4% In March ↗

April 02, 2023

The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.

Via Talk Markets

Cannabis Category Performances Ranged From +8.6% To -7.0% This Week ↗

March 25, 2023

The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example.

Via Talk Markets

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗

March 20, 2023

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

Via Benzinga

Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary ↗

March 17, 2023

Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership...

Via Benzinga

Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder ↗

March 15, 2023

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 15, 2023

Via Benzinga

Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 15, 2023

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.

Via Benzinga

All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD ↗

March 12, 2023

The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD.

Via Talk Markets

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗

March 06, 2023

After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.

Via Benzinga

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

March 03, 2023

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

Via News Direct

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

March 03, 2023

Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce...

Via TheNewswire.com

Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials ↗

March 03, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has...

Via Benzinga

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

February 28, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients...

Via TheNewswire.com

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

February 28, 2023

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

Via News Direct

Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis ↗

February 28, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.